SCHEMBL19836880

SCHEMBL19836880

COC(=O)C/C(=C\c1nc(C)cs1)C(=O)OC

nearest known ligand 0.36

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 1/20 0.34
▸ ALDH1A1 P00352 3/20 0.34
▸ KDM4E B2RXH2 2/20 0.34
▸ NLRP3 Q96P20 1/20 0.34
▸ SMN1; SMN2 Q16637 3/20 0.33
▸ POLB P06746 2/20 0.33
▸ TGFBR1 P36897 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ TSHR P16473 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ MAPK10 P53779 1/20 0.33
▸ RAB9A P51151 4/20 0.33
▸ PTGS2 P35354 1/20 0.33
▸ GRM5 P41594 1/20 0.33
▸ NPC1 O15118 3/20 0.32
▸ HPGD P15428 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19836882 1.00 MAPT (0.34) MAPTALDH1A1KDM4ENLRP3SMN1; SMN2
SCHEMBL20187610 0.78 MAPT (0.41) MAPTALDH1A1KDM4ESMN1; SMN2LMNA
SCHEMBL20187609 0.78 MAPT (0.41) MAPTALDH1A1KDM4ESMN1; SMN2LMNA
SCHEMBL25222326 0.75 TSHR (0.40) MAPTALDH1A1KDM4ESMN1; SMN2POLB
SCHEMBL29136923 0.71 CA12 (0.41) MAPTALDH1A1KDM4ENLRP3SMN1; SMN2
SCHEMBL24149776 0.71 CA12 (0.41) MAPTALDH1A1KDM4ENLRP3SMN1; SMN2
SCHEMBL15174136 0.69 HSD17B10 (0.39) MAPTALDH1A1KDM4ESMN1; SMN2POLB
SCHEMBL13208839 0.67 HSD17B10 (0.45) MAPTALDH1A1KDM4ESMN1; SMN2POLB
SCHEMBL7377051 0.66 RECQL (0.53) MAPT
SCHEMBL7377043 0.66 RECQL (0.53) MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230174556-A1 COMPOUNDS AS PROTEIN KINASE INHIBITORS FOCHON BIOSCIENCES, LTD. (CN) 2023-06-08 — — US disclosed
EP-3224248-B1 CERTAIN PROTEIN KINASE INHIBITORS SHANGHAI FOCHON PHARMACEUTICAL CO LTD (CN) 2021-05-05 — — EP disclosed
US-10328060-B2 Certain protein kinase inhibitors SHANGHAI FOCHON PHARMACEUTICAL CO., LTD. (CN) 2019-06-25 — — US disclosed
US-20180036293-A1 CERTAIN PROTEIN KINASE INHIBITORS SHANGHAI FOCHON PHARMACEUTICAL CO., LTD. (CN) 2018-02-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180036293-A1 CERTAIN PROTEIN KINASE INHIBITORS AKT1, PIK3CA, AKT3 MAPT 2101/4885ALDH1A1 4555/4885KDM4E 2650/4885
US-10328060-B2 Certain protein kinase inhibitors AKT1, PIK3CA, AKT3 MAPT 2101/4885ALDH1A1 4555/4885KDM4E 2650/4885
US-20230174556-A1 COMPOUNDS AS PROTEIN KINASE INHIBITORS PIK3CA, AKT1, PIK3CB MAPT 1343/4885ALDH1A1 4698/4885KDM4E 2381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback